Woman and Man | Between 18 years et 130 years
- | Country :
- France
- | organs :
- Vessie
- | Specialty :
- Immunothérapie - Vaccinothérapie
- Chimiothérapie
Extract
A phase III, randomized, open-label, multi-center, global study to determine the efficacy and safety of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in patients with muscle-invasive bladder cancer.